Literature DB >> 15254806

Vanishing contrast enhancement in malignant glioma after corticosteroid treatment.

H S Zaki1, M D Jenkinson, D G Du Plessis, T Smith, N G Rainov.   

Abstract

Malignant gliomas of the brain typically exhibit on CT or MRI a strong peripheral contrast enhancement area with a variable central zone of necrosis. These tumours are not known to change their radiological appearance and contrast enhancement pattern under systemic steroid treatment--a feature usually associated with primary CNS lymphoma. We report two cases of adult patients with glioblastoma multiforme and atypical hemispherical contrast enhancement initially demonstrated on MRI or CT, which disappeared after dexamethasone administration. At the same time, however, another tumour focus became visible, in both cases localised in the corpus callosum. Histological diagnosis was confirmed by stereotactic biopsy in both cases. This unusual changing pattern of contrast enhancement seems to be associated with multifocal malignant glioma with partial blood-brain barrier disruption modified by dexamethasone, and may present diagnostic difficulties in respect to neuroimaging and selection of target areas for tumour biopsy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254806     DOI: 10.1007/s00701-004-0282-8

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  11 in total

1.  Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression.

Authors:  Madison R Hansen; Edward Pan; Andrew Wilson; Morgan McCreary; Yeqi Wang; Thomas Stanley; Marco C Pinho; Xiaohu Guo; Darin T Okuda
Journal:  J Neurooncol       Date:  2018-06-07       Impact factor: 4.130

Review 2.  Imaging characteristics of toxoplasmosis encephalitis after bone marrow transplantation: report of two cases and review of the literature.

Authors:  C Mueller-Mang; T G Mang; P Kalhs; M M Thurnher
Journal:  Neuroradiology       Date:  2005-11-10       Impact factor: 2.804

3.  Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas.

Authors:  Benjamin M Ellingson; Mark G Malkin; Scott D Rand; Pete S LaViolette; Jennifer M Connelly; Wade M Mueller; Kathleen M Schmainda
Journal:  J Neurooncol       Date:  2010-08-27       Impact factor: 4.130

Review 4.  A systematic approach to the diagnosis of suspected central nervous system lymphoma.

Authors:  Brian J Scott; Vanja C Douglas; Tarik Tihan; James L Rubenstein; S Andrew Josephson
Journal:  JAMA Neurol       Date:  2013-03-01       Impact factor: 18.302

5.  Preoperative prognostic value of dynamic contrast-enhanced MRI-derived contrast transfer coefficient and plasma volume in patients with cerebral gliomas.

Authors:  T B Nguyen; G O Cron; J F Mercier; C Foottit; C H Torres; S Chakraborty; J Woulfe; G H Jansen; J M Caudrelier; J Sinclair; M J Hogan; R E Thornhill; I G Cameron
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-19       Impact factor: 3.825

6.  Glioblastoma presenting with steroid-induced pseudoregression of contrast enhancement on magnetic resonance imaging.

Authors:  Marcus D Mazur; Vinh Nguyen; Daniel W Fults
Journal:  Case Rep Neurol Med       Date:  2012-07-11

7.  Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.

Authors:  Biqi Zhang; Ken Chang; Shakti Ramkissoon; Shyam Tanguturi; Wenya Linda Bi; David A Reardon; Keith L Ligon; Brian M Alexander; Patrick Y Wen; Raymond Y Huang
Journal:  Neuro Oncol       Date:  2016-06-26       Impact factor: 13.029

8.  Benefit of 3T Diffusion-weighted Imaging in Comparison to Contrast-enhanced MR Imaging for the Evaluation of Disseminated Lesions in Primary Malignant Brain Tumors.

Authors:  Yoshihito Kadota; Toshinori Hirai; Hideo Nakamura; Keishi Makino; Shigetoshi Yano; Shinichiro Nishimura; Machiko Tateishi; Minako Azuma; Mika Kitajima; Yasuyuki Yamashita
Journal:  Magn Reson Med Sci       Date:  2016-10-11       Impact factor: 2.471

9.  Exclusion of a brain lesion: is intravenous contrast administration required after normal precontrast magnetic resonance imaging?

Authors:  E J Ives; N Rousset; N Heliczer; M E Herrtage; A E Vanhaesebrouck
Journal:  J Vet Intern Med       Date:  2014-01-27       Impact factor: 3.333

10.  Patient-specific parameter estimates of glioblastoma multiforme growth dynamics from a model with explicit birth and death rates.

Authors:  Li Feng Han; Steffen Eikenberry; Chang Han He; Lauren Johnson; Mark C Preul; Eric J Kostelich; Yang Kuang
Journal:  Math Biosci Eng       Date:  2019-06-11       Impact factor: 2.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.